Mirum Pharmaceuticals Price Target Raised to $195 Following Drug Success

Key Facts

1H.C. Wainwright raised the price target for Mirum Pharmaceuticals to $195 from $140.

2The drug Brelovitug met its primary endpoint in a Phase 3 study for Chronic Hepatitis Delta Virus.

3The company, in partnership with Incyte, received FDA approval for Atebrioz to treat a rare bone disease.

H.C. Wainwright raised the price target for Mirum Pharmaceuticals to $195 from $140. Financial Modeling Prep reported that the revision follows the drug Brelovitug meeting its primary endpoint in a Phase 3 study for Chronic Hepatitis Delta Virus, alongside the company receiving FDA approval for Atebrioz to treat a rare bone disease in partnership with Incyte.

MIRM closed at $89.70 on September 25, 2026, while shares of its partner INCY closed at $123.89 on the same date. These clinical and regulatory milestones in the company's drug pipeline underpin the significant increase in the analyst's valuation target.